Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR2A | P27037 | 1/20 | 0.75 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.75 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 4/20 | 0.45 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL408316 | 0.92 | ACVR2A (0.66) | ACVR2ATGFBR2KMT2ANAMPTGAA | |
| SCHEMBL413843 | 0.92 | ACVR2A (0.78) | ACVR2ATGFBR2KMT2ATRPV1NAMPT | |
| SCHEMBL410503 | 0.91 | ACVR2A (0.68) | ACVR2ATGFBR2KMT2ATRPV1NAMPT | |
| SCHEMBL413609 | 0.90 | ACVR2A (0.70) | ACVR2ATGFBR2KMT2ANAMPTCNR1 | |
| SCHEMBL412507 | 0.90 | ACVR2A (0.64) | ACVR2ATGFBR2KMT2ATRPV1FPR2 | |
| SCHEMBL414446 | 0.90 | ACVR2A (0.64) | ACVR2ATGFBR2FPR2NAMPTKCNH2 | |
| SCHEMBL412926 | 0.90 | ACVR2A (0.64) | ACVR2ATGFBR2KMT2AFPR2NAMPT | |
| SCHEMBL411736 | 0.90 | ACVR2A (0.72) | ACVR2ATGFBR2KMT2ANAMPTMAPK1 | |
| SCHEMBL411765 | 0.88 | ACVR2A (0.67) | ACVR2ATGFBR2KMT2ANAMPTCNR1 | |
| SCHEMBL413602 | 0.87 | ACVR2A (0.66) | ACVR2ATGFBR2NAMPTCNR1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1590347-A1 | ISOTHIAZOLE DERIVATIVES | Pfizer Products Inc. (US) | 2005-11-02 | — | — | EP | claimed |
| WO-2004067530-A1 | ISOTHIAZOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-08-12 | — | — | WO | claimed |
| US-20040147574-A1 | Isothiazole derivatives | PFIZER INC | 2004-07-29 | — | — | US | claimed |
| US-8603818-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2013-12-10 | — | — | US | disclosed |
| US-8298825-B1 | TGF-beta receptor inhibitors to enhance direct reprogramming | THE GENERAL HOSPITAL CORPORATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120021519-A1 | EFFICIENT INDUCTION OF PLURIPOTENT STEM CELLS USING SMALL MOLECULE COMPOUNDS | PRESIDENTS AND FELLOWS OF HARVARD COLLEGE (US) | 2012-01-26 | — | — | US | disclosed |
| EP-1590347-A1 | ISOTHIAZOLE DERIVATIVES | Pfizer Products Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004067530-A1 | ISOTHIAZOLE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-08-12 | — | — | WO | disclosed |
| US-20040147574-A1 | Isothiazole derivatives | PFIZER INC | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147574-A1 | Isothiazole derivatives | SMAD3, SMAD2, TGFBR1 | ACVR2A 85/4885TGFBR2 4/4885KMT2A 2861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.